Europe - FRA:EUZ - DE0005659700 - Common Stock
The current stock price of EUZ.DE is 16.68 EUR. In the past month the price decreased by -6.13%. In the past year, price decreased by -15.63%.
 Symbol   |  Company Name   |  TA   |  FA   |  PE   |  Market Cap   | 
|---|---|---|---|---|---|
| ABL.DE | ABBOTT LABORATORIES | 24.67 | 185.48B | ||
| IUI1.DE | INTUITIVE SURGICAL INC | 62.06 | 165.74B | ||
| 1ISRG.MI | INTUITIVE SURGICAL INC | 61.93 | 165.38B | ||
| BSX.DE | BOSTON SCIENTIFIC CORP | 33.88 | 128.02B | ||
| 2M6.DE | MEDTRONIC PLC | 16.45 | 101.09B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 20.51 | 55.07B | ||
| 1BDX.MI | BECTON DICKINSON AND CO | 12.69 | 44.91B | ||
| BOX.DE | BECTON DICKINSON AND CO | 12.56 | 44.46B | ||
| EWL.DE | EDWARDS LIFESCIENCES CORP | 32.66 | 42.57B | ||
| 1DXCM.MI | DEXCOM INC | 32.47 | 20.50B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 16.5 | 22.88B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 16.47 | 22.83B | 
 Eckert & Ziegler SE is a holding company, which engages in the processing of radio isotopes. The company is headquartered in Berlin, Berlin and currently employs 1,098 full-time employees.  The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
ECKERT & ZIEGLER SE
Robert-Roessle-Str.10
Berlin BERLIN DE
Employees: 1098
Phone: 49309410840
Eckert & Ziegler SE is a holding company, which engages in the processing of radio isotopes. The company is headquartered in Berlin, Berlin and currently employs 1,098 full-time employees. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
The current stock price of EUZ.DE is 16.68 EUR. The price decreased by -1.48% in the last trading session.
ECKERT & ZIEGLER SE (EUZ.DE) has a dividend yield of 0.98%. The yearly dividend amount is currently 0.02.
EUZ.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
ECKERT & ZIEGLER SE (EUZ.DE) has a market capitalization of 1.06B EUR. This makes EUZ.DE a Small Cap stock.
ECKERT & ZIEGLER SE (EUZ.DE) will report earnings on 2025-11-13.
ChartMill assigns a fundamental rating of 7 / 10 to EUZ.DE. Both the health and profitability get an excellent rating, making EUZ.DE a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months EUZ.DE reported a non-GAAP Earnings per Share(EPS) of 0.59. The EPS increased by 16.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.24% | ||
| ROA | 8.35% | ||
| ROE | 16.32% | ||
| Debt/Equity | 0.18 | 
7 analysts have analysed EUZ.DE and the average price target is 22.92 EUR. This implies a price increase of 37.39% is expected in the next year compared to the current price of 16.68.
For the next year, analysts expect an EPS growth of 30.07% and a revenue growth 8.76% for EUZ.DE